Seladelpar

Gilead will present 29 abstracts at the European Association for the Study of the Liver Congress in May 2025, highlighting advancements in treatments for primary biliary cholangitis and viral hepatitis.

Ipsen's Iqirvo (elafibranor) receives FDA accelerated approval as the first dual PPAR alpha/delta agonist and first new therapy in over a decade for primary biliary cholangitis treatment.

The UK's MHRA has approved Gilead's Livdelzi (seladelpar) for adults with primary biliary cholangitis (PBC) who inadequately respond to or cannot tolerate UDCA.

The FDA approved 50 novel drugs in 2024, slightly down from 55 in 2023, while the EMA increased its approvals to 46 from 39 in the previous year.

COUR Pharmaceuticals' CNP-104, a novel therapy for primary biliary cholangitis (PBC), has been granted Orphan Drug Designation by the FDA.